Tiziana Pia Latiano

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Bevacizumab 64%
3. trifluridine tipiracil 44%
4. Oxaliplatin 34%
5. Leucovorin 29%
6. Fluorouracil 29%
7. Cetuximab 29%
8. Crohn Disease 25%
9. Inflammatory Bowel Diseases 25%
10. Ulcerative Colitis 20%
11. Safety 20%
12. XELOX 20%
13. Dihydrouracil Dehydrogenase (NADP) 18%
14. Pancreatic Neoplasms 18%
15. Therapeutics 18%
16. Irinotecan 17%
17. Progression-Free Survival 14%
18. Genes 14%
19. Drug-Related Side Effects and Adverse Reactions 14%
20. Randomized Controlled Trials 12%
21. Disease Progression 12%
22. Drug Therapy 11%
23. Survival 10%
24. Biomarkers 9%
25. Neoplasms 9%
26. Compassionate Use Trials 9%
27. Confidence Intervals 9%
28. Interleukin-33 8%
29. Genotype 8%
30. Esophageal Achalasia 7%
31. Single Nucleotide Polymorphism 7%
32. Neoplasm Metastasis 7%
33. Control Groups 7%
34. Quality of Life 6%
35. Genetic Polymorphisms 6%
36. Neutropenia 6%
37. Mutation 6%
38. Adenocarcinoma 6%
39. Gene Expression 5%
40. Elderly 5%
41. Lactate Dehydrogenases 5%
42. Panitumumab 5%
43. Genome 5%
44. gemcitabine 5%
45. nintedanib 5%